

**MEDIA RELEASE**

**VivaZome and Cytiva (formerly part of GE HealthCare Life Sciences) enter into an agreement  
on downstream technology for exosome purification**

**21<sup>st</sup> May 2020; Melbourne Australia and Uppsala, Sweden:** VivaZome Therapeutics Pty Ltd (“VivaZome”) and Cytiva, formerly part of GE Healthcare Life Sciences, have entered into an agreement where Cytiva’s range of purification technologies, including Fibro, will be applied to VivaZome’s selected exosome fractions, with the goal of developing a high-efficiency downstream separation and concentration process for exosome production by VivaZome.

Under the agreement, VivaZome will provide substantial quantities of exosome-rich, cell culture supernatant produced by VivaZome’s preferred cell type. Cytiva’s Next Generation Resins Team, located in Uppsala in Sweden, will use the VivaZome material to evaluate Cytiva chromatography resins and fibre materials for their potential to separate and concentrate exosomes, with an emphasis on demonstrating high purity, very fast flow rates and scale-ability.

VivaZome’s Chief Executive Officer, Dr David Haylock, stated: “VivaZome is delighted and excited to enter into this agreement with Cytiva. As a major global life sciences company, Cytiva brings high-level expertise extensive experience and the latest technologies to the table. Cytiva and VivaZome recognise that development of a high-efficiency downstream separation and concentration process is key to manufacture of therapeutic exosomes and realising their therapeutic potential.”

Dr Peter Guterstam, Product Manager in the Next Generation Resins team at Cytiva said: “Working with VivaZome, we will leverage our expertise and purification portfolio and VivaZome’s experience and analytical capabilities to develop a high productivity and scalable downstream platform for exosome purification that will help accelerate the development of novel therapeutics.”

VivaZome’s Chair, Dr Ian Nisbet, commented: “Following our recent announcement regarding joint project work with Toolgen of Korea, this collaboration with Cytiva further demonstrates VivaZome’s capacity to reach out internationally, thus building our technology base and our global reputation.”

For further information, contact:

VivaZome Therapeutics Pty Ltd  
Dr David Haylock, CEO  
David.haylock@vivazome.com  
Phone: +61 (0) 439 617 657

Cytiva  
Colleen Connolly  
Senior Communications Manager  
[Colleen.Connolly@cytiva.com](mailto:Colleen.Connolly@cytiva.com) Phone: +1 774 245 3893



## **About VivaZome Therapeutics Pty Ltd**

VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately held Australian biotech company, with headquarters at the La Trobe University Technology Enterprise Centre. VivaZome was formed to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on critical limb ischaemia (CLI).

CLI is a debilitating disease caused by reduced blood flow, most often in the legs. It affects more than 4 million people worldwide, with an estimated treatment cost of over \$10B pa in the US alone. Existing treatments are largely surgical interventions including, in advanced disease, amputation. There is a huge need for new treatments, particularly pharmaceutical interventions to prevent or delay disease progression.

VivaZome is developing new technologies and generating intellectual property and proprietary materials that are applicable generically to exosome therapies. They will also underpin the Company's development of angiogenic exosomes for the treatment of CLI.

The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.

VivaZome acknowledges the support of the Department of Industry, Science, Energy and Resources through the CRC-P program, and the efforts of its CRC-P partners, La Trobe University and SeerPharma Pty Ltd.

For more information, please visit [www.vivazome.com](http://www.vivazome.com)

## **About Exosomes**

Exosomes are small particles released by cells. They are a key effector in communication between cells and have the potential to become an off-the-shelf medicine without the technical problems of cell therapies. Currently exosomes are made at small scale – the VivaZome project aims to develop a large-scale, advanced manufacturing process for exosomes.